This is the second case report [1] on a therapeutic response to combined BRAF and MEK-targeted therapy in a recurrent papillary craniopharyngioma with genetically confirmed BRAFV600E mutation. Here, MAP2K7 is linked to Papillary Craniopharyngioma.